ClinicalTrials.Veeva

Menu

Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer

S

Sunnybrook Health Sciences Centre

Status

Enrolling

Conditions

Breast Cancer

Treatments

Device: Quantitative ultrasound to guide adaptive chemotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT04050228
308-2017

Details and patient eligibility

About

The primary objective of this study is to assess the feasibility of randomizing breast cancer patients to quantitative ultrasound to guide adaptive Neoadjuvant Chemotherapy as compared to standard clinical monitoring and therapy. The Investigators have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be used to detect cell death in vitro, in situ and in vivo. The method can detect different forms of cell death and has been demonstrated to be sensitive to apoptotic, necrotic and mitotic cell death. By detecting cell death early in a treatment on the order of hours to days, rather than traditional anatomical assessments that take place weeks to months after the completion of therapy, ineffective therapies could be switched to more efficacious treatments or aggressive salvage therapy which has shown to already benefit patients. The overarching goal of this research is to transform the delivery of neoadjuvant chemotherapy using quantitative ultrasound (QUS), which is non-invasive, inexpensive and portable.

Full description

This study phase II will demonstrate the use of quantitative ultrasound to guide adaptive chemotherapy for patients with breast cancer. The primary endpoint will be measurement of improved response rate locally. This trial will enroll 240 randomized breast cancer patients to be assess with quantitative ultrasound to guide adaptive neoadjuvant chemotherapy as compared to standard clinical monitoring and therapy. We will evaluate the safety of its use and expect equivalence in this small patient population. This will allow for more accurate estimation of a needed sample size for a phase III superiority trial.

Enrollment

240 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Women ≥ 18 years of age
  2. Diagnosis of breast cancer with a primary tumour >2cm in size
  3. With conditions meeting criteria for chemotherapy administration
  4. Normal hematological blood counts (hemoglobin ≥ 100 g/l, platelet count ≥ 100 x 109, absolute neutrophil count ≥ 2.0 x109 cells per L)
  5. Creatinine ≤175 µmol/L
  6. Liver enzymes (AST and ALT) ≤ 1.5 times upper limit of normal
  7. Cardiac function (left ventricular ejection fraction) ≥55%
  8. Eligible for neoadjuvant chemotherapy.

Exclusion criteria

  1. Inflammatory breast cancer
  2. Contraindications to neoadjuvant treatment including pregnancy or lactation
  3. Past medical history of connective tissue disease
  4. Past history of dermatologic disease involving the breast
  5. Eastern Cooperative Group Status (ECOG) ≥3
  6. No peripheral neuropathy of a severity of grade ≥2
  7. Evidence of distant metastatic disease
  8. Known sensitivity to components present in ultrasound gel.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

240 participants in 2 patient groups

Standard Neoadjuvant Chemotherapy Monitoring
No Intervention group
Description:
Patients who will be randomized to the control arm with Standard Neoadjuvant Chemotherapy Monitoring will receive Phase I chemotherapy consisting of anthracycline-based treatment followed by Phase II chemotherapy consisting of taxane-based treatment. Patients will be imaged but no modifications to treatment will occur in this trial arm depending on response by quantitative ultrasound.
Adaptive Chemotherapy Monitoring
Experimental group
Description:
Patients who will be randomized to the experimental arm Adaptive Chemotherapy Monitoring and demonstrate Response (+) will continue until standard chemotherapy is completed. For patients who do not demonstrate response after 4 weeks of chemotherapy, an early switch to the second phase of chemotherapy could occur (Phase II/Taxane) At the discretion of the treating medical oncologist. Patients will undergo Quantitative Ultrasound on the following time points: Pre-treatment, Weeks 1, 4, 8, 12 and Pre-Operatively. These QUS time points correspond to the following chemotherapy times.
Treatment:
Device: Quantitative ultrasound to guide adaptive chemotherapy

Trial contacts and locations

1

Loading...

Central trial contact

Gregory J Czarnota, PhD, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems